European Pharmacovigilance Congress 2025
Conference overview
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences for the very high scientific content.
As in previous editions, the EUPV congress 2025 is asssured by the esteemed Scientific Advisory Group: a team of internationally renown key opinion leaders in charge of defining the congress content and identifying the most knowledgeable, prestigious and eloquent speakers.
This year the scientific value of the congress will further increase thanks to the collaboration of the Institute of Pharmacovigilance.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
EUPV Congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
The 8th European Pharmacovigilance Congress: speaker abstracts 2024
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress 2025 will be a mixed event!
19-20 November | Virtual 9 am – 6 pm
27 November | PV Workshop + Evening Cocktail, NH Milano Congress Centre 5 – 9 pm
28 November | Face to face, NH Milano Congress Centre 9 am – 5 pm
EVENING COCKTAIL November 27 from 6 to 9 pm
At the conference venue, PEC organizes a Welcome evening cocktail that will take place together with interesting workshops. Reserve your place to meet and network with your colleagues and experts!
This year the congress will include:
– 22 Topics
– 18 interactives round tables
– 6 virtual parallel sessions
– 2 face-to-face parallel workshops
– 1 Lectio Magistralis
Why attend?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
Who should attend?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
AGENDA 2025
Discover the Congress agenda here.
NOVEMBER 19 | Virtual
Signal detection is a fundamental task to identify the new or evolving risks associated with medicinal products. This session will discuss how advancements in technology are shaping this practice emphasizing the critical role of high-quality data in generating meaningful safety signals.
Reducing the frequency and severity of adverse reactions—especially important ones, and ideally preventing them altogether—is a key activity to ensure that a medication maintains a positive benefit-risk balance. In this session, we will discuss how to support patient adherence to risk minimization measures, as well as explore how these measures can sometimes lead to unintended consequences.
Devices are being increasingly used together with medicinal products and new regulatory frameworks have been introduced to assess the safety of these combination products. However, despite their growing importance, these topics remain frequently under discussed; therefore, this session is a valuable learning opportunity.
Real-world evidence is a hot topic that has been recently presented in CIOMS XIII report. Building on the learnings of this report, this session will focus on leveraging diverse real-world data sources to generate meaningful safety insights beyond traditional methodologies.
The safety of cosmetics has lots of commonalities with pharmacovigilance but is neglected by most pharmacovigilance scientists. This session is an opportunity to learn more about this science that is closely related to pharmacovigilance.
Everything we do in pharmacovigilance is for the benefit of the patients. Engaging with patient representatives, incorporating their perspectives, listening to what they have to say on the safety of medicinal products and taking consequential actions is of crucial importance to maximize the benefit-risk balance of medicinal products and to build trust.
Inspections play a key role in ensuring compliance with local pharmacovigilance requirements. This session highlights the paramount importance of understanding them and integrating them in a global pharmacovigilance system.
Benefit-risk evaluation depends on data. In the case of rare diseases, their limited prevalence means that data, especially in the pre-marketing phase, is often scarce. In this lectio magistralis, we will explore how to effectively use the available data to conduct benefit-risk assessments for drugs under development for rare diseases, and how these assessments can inform and guide the development process.
NOVEMBER 20 | Virtual
Regulatory authorities monitor safety data from before a medicine is first administered to humans until it is withdrawn from the market. In this session, you’ll hear directly from regulators about how they maintain oversight of a medicine’s safety throughout its entire life cycle.
The ultimate goal of pharmacovigilance has always been to ensure patients receive treatments with the most favorable benefit-risk profile. CIOMS XII working group is providing the most up to date suggestions on how to evaluate benefit-risk.
The label has a critically important role in conveying safety information to healthcare professional and patients. This session examines how labels can effectively communicate the necessary information on how to maximize drug benefits and reduce their risks.
AI is the buzzword in PV, but do we know how to implement it according to regulatory requirements and expectations?
Aggregate reports, highlighting the latest and cumulative safety information for every medicinal product during its whole life cycle, are required by regulatory authorities in almost every country. This session reviews some global requirements, the challenges of non-harmonized regulations and emerging trends in safety reporting.
Pharmacovigilance is not only about processes, regulations and efficiency. Most importantly it`s about science. This session offers a deeper understanding of how the interactions between the immune system and a medicinal product cause adverse reactions.
A session showcasing real-world examples of AI technologies to streamline pharmacovigilance workflow and improve outcomes.
NOVEMBER 28 | Milan
An overview of how to overcome the current and future challenges we are facing and will tackle in pharmacovigilance. What are the lessons we have learned and how we can leverage them to make our work more meaningful.
Personalized medicine and treatment is one of the most recent advancements in the medical field. Where are we with personalized pharmacovigilance?
Topic 1 – The New EU PV Regulation 2025/1466: Impact on Pharmacovigilance Operations under Implementing Regulation 520/2012 – challenges and opportunities
Topic 2 – Effective Regulatory Intelligence for Navigating Global PV Regulation and Implementation
Gaining insights directly from PRAC members and European regulators on how benefit-risk assessments are conducted across the EU regulatory framework.
As all sciences, also pharmacovigilance has and is rapidly evolving due to new technologies and methodologies. PV professionals need to continuously adapt by updating their skillset. This session outlines the newly required competencies to meet emerging scientific and technological demands.
The session that traditionally closes EU PV congress: compliance is the “ticket to ride” of every pharmacovigilance system that gives credibility to the work we do every day.
Scientific Advisory Group 2025

Felix Arellano
Senior Vice President and the Global Head of Safety & Risk Management | Roche

Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK

Glyn Belcher
Honorary Member Scientific Advisory Group EUPV Congress 2025

Mattia Calissano
VP, Medical | SSI Strategy

Gian Nicola Castiglione
Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Head of Pharmacovigilance and QPPV

Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance

Giovanni Furlan
Head Medical Safety Operations | Sandoz Germany

Calin A. Lungu
DDCS S.A., CEO

Hrvoje Maček
VP, Medical & Scientific Affairs, EU QPPV | PrimeVigilance

Valentina Mancini
Senior Director Pharmacovigilance, QPPV | Shionogi Europe

Jan Petracek
CEO | iVigee, Director | Institute of Pharmacovigilance

Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech
SPEAKERS 2025 IN PROGRESS

Marko Korenjak
President of the European Liver Patients’ Association, former PRAC member

Ana Sofia Martins
PRAC Member | INFARMED, I.P. – Portugal

Petar Mas
PRAC HALMED

João A. Pedras-Vasconcelos
Senior Pharmaceutical Scientist (Product Quality and Immunogenicity) CDER Integrative Immunogenicity Working Group Co-chair – FDA (tbc)

Sophia Trantza
Senior Pharmacovigilance Expert former PRAC Member Greece

Antonella Caselli
Senior Clinical & Safety Assessor | Italian Medicines Agency (AIFA), Italy (Tbc)

Cristina Arizmendi Vélez
Chief of Cosmetovigilance and Safety of Cosmetic Products | AEMPS

Lembit Rägo
Secretary-General | Council for International
Organizations of Medical Sciences (CIOMS)

Pilar Rayón
PRAC AEMPS

Kendal Harrison
Head of Vigilance Development | MHRA

Lina Seibokiene
Senior expert at the Pharmacovigilance and Poison Information Unit, SMCA / PRAC alternate member.
Elena Giovani
Head of the GVP Inspection Office | AIFA (Tbc)

Ana Maria Velasco Calle
GCP/GVP Inspector from the Spanish Agency of Medicines and Medical Devices

Dirk Mentzer
Head of Pharmacovigilance | Paul-Ehrlich-Institut (PEI)

Elena Prokofyeva
Head of safety in clinical trials unit, DG Post, FAMHP

Fazil Afzal
Senior Medical Assessor at Medicines and Healthcare products Regulatory Agency (MHRA) (tbc)

John Borg
Director Post-Licensing | Malta Medicines Authority

Robert Ball
Deputy Director | Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research, FDA

François Haguinet
Associate Director for Safety and Quantitative Innovation | GSK – Belgium

Anita Blackburn
Labeling Lead | Fortrea

Taxiarchis Botsis
Associate Professor | Johns Hopkins University School of Medicine – USA

Giuseppe Curigliano
Professor of Medical Oncology | University of Milano and European Institute of Oncology, IRCCS

Vjera Bilusic Vundac
Senior Director, Medical Writing | Primevigilance Ltd.-Croatia

Barbara De Bernardi
EU & UK Pharmacovigilance Qualified Person, VP, Head of Global QPPV Office Worldwide Medical & Safety | Pfizer

Ahmed Diaa Eldin
CEO | Baupharma

Margherita D’Antuono
EU-UK QPPV | Piramal Critical Care

Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University; Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia

Tina Amini
Director TA MedTech & Combination Products Consulting Ltd

Panos Tsintis
Medical Director | PLM Med Ltd – UK

Hanae Bourji Chergui
Regulatory Affairs Senior Specialist | Becton and Dickinson

Ayman Ayoub
VP Safety Evaluation & Risk Management | GSK

Marie-Laure Kurzinger
Associate VP, Head of Pharmacoepidemiology – General Medicines, Pharmacovigilance and Patient Safety | Sanofi

Rory Littlebury
Head of PV System Oversight and QPPV Office | GSK – UK

Rajat Mohindra
Principal Medical Director, Precision Safety, Product Development Safety | F. Hoffmann-La Roche Ltd – SWISS

Valeria Di Clemente
Director Pharmacovigilance EU Cluster and LATAM | Baxter

Natasa Mihajlovic
Managing Director | Nostra Pharma

Antoine Pariente
Professor of Clinical Pharmacology and Pharmacoepidemiology, Head of the Public Health Research Department | Univ. Bordeaux

Hadir Rostom
President of ISoP Egypt Chapter

Adrian Roth
Principal Scientific Director Precision Safety, Pharma Development | Roche – Swiss

Michael Glaser
Safety Innovation Technology Director | GSK – USA

Ilaria Grisoni
Exec. Dir., Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals

Mariangela Amoroso
Country Medical Lead | Sanofi Italy

Lisa Stagi
Patient Safety Country Cluster Lead | Roche

Nancy Dreyer
Chief Scientific Officer retired IQVIA and Professor | Univ of North Carolina, Chapel Hill – USA

Michael Von Forstner
Head of Safety Science| Sobi

Fabio De Gregorio
Vice President, Head of Safety | Shionogi Europe – UK

Klaudija Marijanovic Barac
Sr. Director, Head of Teva Periodic reports and risk management Centre | Teva

Antonella Fretta
Senior Director | Pfizer

Valentina Strammiello
Interim Executive Director | European Patients’ Forum

Alberto Gramaccioli
Director of Quality Management and Inspection | Pfizer

Sabine Fuerst-Recktenwald
Head Clinical Development Pediatric Center of Excellence | Novartis Pharma AG

Snehal Haribhau Gaykar
Associate Director, Global Risk Management | Sandoz

Trevor Mill
Senior Vice President | SSI Strategy

Maddalena Lino
Safety Risk Lead Director | Pfizer

Paola Kruger
Expert Patient | EUPATI (European Patient’s Academy for Therapeutic Innovation)

David Chonzi
Medical Director | PV Safety Solutions

Mercedina del Papa
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance

Elena Alcaraz
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance

Sara Vodanovic
Director, Regulatory Intelligence and Analytics | PrimeVigilance

Dimitris Zampatis
Director Product Patient Safety (DPPS) | Sandoz

Catherine Tchinou
Head Medical Safety Biopharma | Sandoz

Igor Copot
Executive Director of Safety Systems | Primevigilance

Gabrièle Piaton-Breda
Research & Innovation Director | PLG
MEDIA PARTNER/COLLABORATIONS/SPONSORS 2025 IN PROGRESS
Sage
Scientific Media Partner

Sage
Scientific Media Partner
Published by SAGE, Therapeutic Advances in Drug Safety (Impact Factor: 3.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: shasha.sharief@sagepub.co.uk
Twitter: @TADrugSafety
Visit our website »
Institute of Pharmacovigilance
Collaboration

Institute of Pharmacovigilance
Collaboration
Founded in 2015, the Institute of Pharmacovigilance (IPV) is a not-for-profit, non-governmental global organization with a clear goal – to elevate the pharmacovigilance industry by competency and seniority certification.
In 2020, IPV partnered with the International Society of Pharmacovigilance (ISoP) to develop the Global Pharmacovigilance Professional Certification (GPPC), creating a globally recognized standard for PV professionals. The certification works with competency standards including knowledge, skills and attitudes suitable for every role in pharmacovigilance.
Committed to continuous innovation, IPV regularly updates its programs to reflect the latest advancements, ensuring certified professionals have practical knowledge and skills they can apply in their jobs immediately.
Visit our website »
Baupharma
Silver Sponsor

Baupharma
Silver Sponsor
Baupharma, headquartered in Prague, is a premier pharmaceutical service provider with over 25 years of industry experience. Our international team offers comprehensive services—including pharmacovigilance, regulatory affairs, medical writing, batch release and distribution, translations, and clinical research—across the EU, MENA region, CIS, Africa, USA, LATAM, and beyond. With offices in Czech Republic, Saudi Arabia, UAE and Egypt, we ensure efficient project management and collaboration, delivering tailored solutions that meet the unique needs of each market.
Visit our website »
Clinpharma
Exhibitor

Clinpharma
Exhibitor
Clinpharma was born from the desire to offer our customers, operating in the chemical-pharmaceutical sector , a complete range of consultancy services. Each project represents an opportunity for us to demonstrate a solid set of skills and make use of a vast wealth of resources. Our objective is to provide a complete consultancy service to Pharmaceutical companies relating to pharmacovigilance activities (pre and post-marketing), cosmetovigilance, phytovigilance and Supervision of Medical Devices, Regulatory Affairs, Scientific Service, Market access and preparation of the price and reimbursement dossier . The company provides its consultancy in compliance with current European and national regulations and guidelines.
Visit our website »
Insuvia
Exhibitor

Insuvia
Exhibitor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visit our website »
iVigee
Platinum Sponsor

iVigee
Platinum Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the ‘instant pharmacovigilance department’, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visit our website »
MakingLife
Media Partner

MakingLife
Media Partner
MakingLife is a publishing house and communications agency specializing in the pharmaceutical sector. It combines editorial expertise with strategic communication to provide high-value scientific content for B2B audiences. Through magazines (papaer and digital) and digital platforms, such as the MakingConnect community, MakingLife supports pharmaceutical companies and their supply chain in improving visibility and promoting innovation. Its multidisciplinary team combines scientific accuracy, creative storytelling and market knowledge to design communication tools. Furthermore, through MakingEducation, MakingLife offers its customers a training service dedicated to the pharma sector.
Visit our website »
Max Application
Exhibitor

Max Application
Exhibitor
Max Application is an IT company specialized in software solutions and focused on continuity, competence and passion in service.
Oracle partner for over 20 years, it offers cloud and on-premise solutions for sectors such as textile manufacturing, automotive and in mainly healthcare. The flagship of the latter is SafetyDrugs, the leading safety database for pharmacovigilance in Italy, accompanied by the Business Intelligence module, essential for Signal Detection.
Always committed to innovation, now part of Abacus Group, it benefits from the synergies and opportunities offered by this strategic partnership in areas such as IT infrastructure, cybersecurity, system integration and artificial intelligence.
Visit our website »
Medical Affairs Consulting
Exhibitor

Medical Affairs Consulting
Exhibitor
Our goal is to ensure excellence in Pharmacovigilance, Medical Information and promoting a culture of Change in a Kaizen perspective throughout the drug life cycle.
Since 2001, our team has provided in-depth experience in the pharmaceutical industry to support our Clients’ needs in managing:
– complex pharmacovigilance processes (QPPV, Deputy-QPPV, safety database, case-processing, aggregated reports, signal detection, literature search, Eudravigilance, Art.57, QAPV, SOPs);
– Scientific training activities for the sales force.
– Support for the preparation, in compliance with the current regulations, of advertising and scientific information materials for pharmaceutical and medical device companies.
– Management consultancy with expertise in Lean Thinking and Kaizen Culture.
Visit our website »
Nextrove
Exhibitor

Nextrove
Exhibitor
Nextrove is a global life sciences systems integrator and professional services leader, trusted by over 150 organizations worldwide — including the top 10 pharma.
We solve complex challenges and deliver end-to-end solutions: from developing and hosting technology to system migrations, upgrades, and managed services across the entire pharmacovigilance chain.
Our proprietary Progressive Suite is system-agnostic technology designed for seamless integration, augmenting organization’ existing setups, while enabling smooth workflows and operational efficiency.
Dedicated exclusively to Pharmaceutical, Biotech, and CROs, Nextrove empowers organizations to optimize operations, strengthen compliance, and deliver safer outcomes for patients — empowering pharmaceutical companies to improve patient safety.
Visit our website »
NostraPharma
Gold Sponsor

NostraPharma
Gold Sponsor
Founded in 2008, NostraPharma is a leading consultancy with ISO 9001:2015 certification, specializing in pharmacovigilance (PV), quality, and training. With over 900 years of combined expertise, we offer customized, high-quality solutions to support clients throughout the PV and quality lifecycle. Our commitment to excellence ensures personalized services, enabling businesses to confidently navigate regulatory requirements. Key services include strategic PV/Quality consultancy, AI/algorithm and GxP auditing, QPPV, PSMF, inspection support, and PV system setup and improvement. We excel in managing complex situations, providing clients with the expertise to overcome regulatory challenges effectively and efficiently.
Visit our website »
PrimeVigilance
Gold Plus Sponsor

PrimeVigilance
Gold Plus Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan. Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs. PrimeVigilance provides pharmacovigilance solutions to over 300 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases, stretching to more than 100 countries.
Visit our website »
ProductLife Group/Pharma D&S/LifeBee/Callisto Pharma Group
Exhibitor

ProductLife Group/Pharma D&S/LifeBee/Callisto Pharma Group
Exhibitor
ProductLife Group’s mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions.
Since 30 years, PLG supports clients through the entire product life cycle, combining local expertise with global reach spanning more than 150 countries. It provides consulting and outsourcing services in the areas of regulatory affairs, quality and compliance, market access, vigilances and medical information, covering both established products and innovative therapeutics & diagnostics.
With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.
Visit our website »
RxLogix
Exhibitor

RxLogix
Exhibitor
Ensuring patient safety while advancing medical and scientific research is vital to life sciences companies. RxLogix is a one-stop-shop for all pharmacovigilance needs, applying the most recent technology advances like machine learning, artificial intelligence, and best practice methodological approaches. RxLogix experienced team of business and technology innovators work with pharmacovigilance and risk management professionals to help increase the compliance, productivity, and quality for the entire drug safety value chain thus ensuring patient safety.
Visit our website to learn more or to schedule a demo.
Visit our website »
Become a sponsor
Don’t miss the chance to be a European Pharmacovigilance Congress 2025 sponsor!
Contact us to learn about our sponsorship packages, you will have the opportunity to:
• Deliver a talk in person or online
• Conduct a parallel session during the day in Milan
• Network and connect with your target customers
Conference Venue
Step 1
On November 19-20 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
COCKTAIL DINNER November 27, 2025 (NH Milano Congress Centre, in Assago, Milan)
Let’s finally meet face to face in Milan on November 28! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
By plane
From Malpensa Airport:
-
- take the bus to the central station, then the subway towards Assago Milanofiori Forum
- take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.
From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.
By train
From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.
By tram
From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.
Conference overview
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences for the very high scientific content.
As in previous editions, the EUPV congress 2025 is asssured by the esteemed Scientific Advisory Group: a team of internationally renown key opinion leaders in charge of defining the congress content and identifying the most knowledgeable, prestigious and eloquent speakers.
This year the scientific value of the congress will further increase thanks to the collaboration of the Institute of Pharmacovigilance.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
EUPV Congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
The 8th European Pharmacovigilance Congress: speaker abstracts 2024
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress 2025 will be a mixed event!
19-20 November | Virtual 9 am – 6 pm
27 November | PV Workshop + Evening Cocktail, NH Milano Congress Centre 5 – 9 pm
28 November | Face to face, NH Milano Congress Centre 9 am – 5 pm
EVENING COCKTAIL November 27 from 6 to 9 pm
At the conference venue, PEC organizes a Welcome evening cocktail that will take place together with interesting workshops. Reserve your place to meet and network with your colleagues and experts!
This year the congress will include:
– 22 Topics
– 18 interactives round tables
– 6 virtual parallel sessions
– 2 face-to-face parallel workshops
– 1 Lectio Magistralis
Why attend?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
Who should attend?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
AGENDA 2025
Discover the Congress agenda here.
NOVEMBER 19 | Virtual
Signal detection is a fundamental task to identify the new or evolving risks associated with medicinal products. This session will discuss how advancements in technology are shaping this practice emphasizing the critical role of high-quality data in generating meaningful safety signals.
Reducing the frequency and severity of adverse reactions—especially important ones, and ideally preventing them altogether—is a key activity to ensure that a medication maintains a positive benefit-risk balance. In this session, we will discuss how to support patient adherence to risk minimization measures, as well as explore how these measures can sometimes lead to unintended consequences.
Devices are being increasingly used together with medicinal products and new regulatory frameworks have been introduced to assess the safety of these combination products. However, despite their growing importance, these topics remain frequently under discussed; therefore, this session is a valuable learning opportunity.
Real-world evidence is a hot topic that has been recently presented in CIOMS XIII report. Building on the learnings of this report, this session will focus on leveraging diverse real-world data sources to generate meaningful safety insights beyond traditional methodologies.
The safety of cosmetics has lots of commonalities with pharmacovigilance but is neglected by most pharmacovigilance scientists. This session is an opportunity to learn more about this science that is closely related to pharmacovigilance.
Everything we do in pharmacovigilance is for the benefit of the patients. Engaging with patient representatives, incorporating their perspectives, listening to what they have to say on the safety of medicinal products and taking consequential actions is of crucial importance to maximize the benefit-risk balance of medicinal products and to build trust.
Inspections play a key role in ensuring compliance with local pharmacovigilance requirements. This session highlights the paramount importance of understanding them and integrating them in a global pharmacovigilance system.
Benefit-risk evaluation depends on data. In the case of rare diseases, their limited prevalence means that data, especially in the pre-marketing phase, is often scarce. In this lectio magistralis, we will explore how to effectively use the available data to conduct benefit-risk assessments for drugs under development for rare diseases, and how these assessments can inform and guide the development process.
NOVEMBER 20 | Virtual
Regulatory authorities monitor safety data from before a medicine is first administered to humans until it is withdrawn from the market. In this session, you’ll hear directly from regulators about how they maintain oversight of a medicine’s safety throughout its entire life cycle.
The ultimate goal of pharmacovigilance has always been to ensure patients receive treatments with the most favorable benefit-risk profile. CIOMS XII working group is providing the most up to date suggestions on how to evaluate benefit-risk.
The label has a critically important role in conveying safety information to healthcare professional and patients. This session examines how labels can effectively communicate the necessary information on how to maximize drug benefits and reduce their risks.
AI is the buzzword in PV, but do we know how to implement it according to regulatory requirements and expectations?
Aggregate reports, highlighting the latest and cumulative safety information for every medicinal product during its whole life cycle, are required by regulatory authorities in almost every country. This session reviews some global requirements, the challenges of non-harmonized regulations and emerging trends in safety reporting.
Pharmacovigilance is not only about processes, regulations and efficiency. Most importantly it`s about science. This session offers a deeper understanding of how the interactions between the immune system and a medicinal product cause adverse reactions.
A session showcasing real-world examples of AI technologies to streamline pharmacovigilance workflow and improve outcomes.
NOVEMBER 28 | Milan
An overview of how to overcome the current and future challenges we are facing and will tackle in pharmacovigilance. What are the lessons we have learned and how we can leverage them to make our work more meaningful.
Personalized medicine and treatment is one of the most recent advancements in the medical field. Where are we with personalized pharmacovigilance?
Topic 1 – The New EU PV Regulation 2025/1466: Impact on Pharmacovigilance Operations under Implementing Regulation 520/2012 – challenges and opportunities
Topic 2 – Effective Regulatory Intelligence for Navigating Global PV Regulation and Implementation
Gaining insights directly from PRAC members and European regulators on how benefit-risk assessments are conducted across the EU regulatory framework.
As all sciences, also pharmacovigilance has and is rapidly evolving due to new technologies and methodologies. PV professionals need to continuously adapt by updating their skillset. This session outlines the newly required competencies to meet emerging scientific and technological demands.
The session that traditionally closes EU PV congress: compliance is the “ticket to ride” of every pharmacovigilance system that gives credibility to the work we do every day.
Scientific Advisory Group 2025

Felix Arellano
Senior Vice President and the Global Head of Safety & Risk Management | Roche

Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK

Glyn Belcher
Honorary Member Scientific Advisory Group EUPV Congress 2025

Mattia Calissano
VP, Medical | SSI Strategy

Gian Nicola Castiglione
Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Head of Pharmacovigilance and QPPV

Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance

Giovanni Furlan
Head Medical Safety Operations | Sandoz Germany

Calin A. Lungu
DDCS S.A., CEO

Hrvoje Maček
VP, Medical & Scientific Affairs, EU QPPV | PrimeVigilance

Valentina Mancini
Senior Director Pharmacovigilance, QPPV | Shionogi Europe

Jan Petracek
CEO | iVigee, Director | Institute of Pharmacovigilance

Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech
SPEAKERS 2025 IN PROGRESS

Marko Korenjak
President of the European Liver Patients’ Association, former PRAC member

Ana Sofia Martins
PRAC Member | INFARMED, I.P. – Portugal

Petar Mas
PRAC HALMED

João A. Pedras-Vasconcelos
Senior Pharmaceutical Scientist (Product Quality and Immunogenicity) CDER Integrative Immunogenicity Working Group Co-chair – FDA (tbc)

Sophia Trantza
Senior Pharmacovigilance Expert former PRAC Member Greece

Antonella Caselli
Senior Clinical & Safety Assessor | Italian Medicines Agency (AIFA), Italy (Tbc)

Cristina Arizmendi Vélez
Chief of Cosmetovigilance and Safety of Cosmetic Products | AEMPS

Lembit Rägo
Secretary-General | Council for International
Organizations of Medical Sciences (CIOMS)

Pilar Rayón
PRAC AEMPS

Kendal Harrison
Head of Vigilance Development | MHRA

Lina Seibokiene
Senior expert at the Pharmacovigilance and Poison Information Unit, SMCA / PRAC alternate member.
Elena Giovani
Head of the GVP Inspection Office | AIFA (Tbc)

Ana Maria Velasco Calle
GCP/GVP Inspector from the Spanish Agency of Medicines and Medical Devices

Dirk Mentzer
Head of Pharmacovigilance | Paul-Ehrlich-Institut (PEI)

Elena Prokofyeva
Head of safety in clinical trials unit, DG Post, FAMHP

Fazil Afzal
Senior Medical Assessor at Medicines and Healthcare products Regulatory Agency (MHRA) (tbc)

John Borg
Director Post-Licensing | Malta Medicines Authority

Robert Ball
Deputy Director | Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research, FDA

François Haguinet
Associate Director for Safety and Quantitative Innovation | GSK – Belgium

Anita Blackburn
Labeling Lead | Fortrea

Taxiarchis Botsis
Associate Professor | Johns Hopkins University School of Medicine – USA

Giuseppe Curigliano
Professor of Medical Oncology | University of Milano and European Institute of Oncology, IRCCS

Vjera Bilusic Vundac
Senior Director, Medical Writing | Primevigilance Ltd.-Croatia

Barbara De Bernardi
EU & UK Pharmacovigilance Qualified Person, VP, Head of Global QPPV Office Worldwide Medical & Safety | Pfizer

Ahmed Diaa Eldin
CEO | Baupharma

Margherita D'Antuono
EU-UK QPPV | Piramal Critical Care

Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University; Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia

Tina Amini
Director TA MedTech & Combination Products Consulting Ltd

Panos Tsintis
Medical Director | PLM Med Ltd – UK

Hanae Bourji Chergui
Regulatory Affairs Senior Specialist | Becton and Dickinson

Ayman Ayoub
VP Safety Evaluation & Risk Management | GSK

Marie-Laure Kurzinger
Associate VP, Head of Pharmacoepidemiology – General Medicines, Pharmacovigilance and Patient Safety | Sanofi

Rory Littlebury
Head of PV System Oversight and QPPV Office | GSK – UK

Rajat Mohindra
Principal Medical Director, Precision Safety, Product Development Safety | F. Hoffmann-La Roche Ltd – SWISS

Valeria Di Clemente
Director Pharmacovigilance EU Cluster and LATAM | Baxter

Natasa Mihajlovic
Managing Director | Nostra Pharma

Antoine Pariente
Professor of Clinical Pharmacology and Pharmacoepidemiology, Head of the Public Health Research Department | Univ. Bordeaux

Hadir Rostom
President of ISoP Egypt Chapter

Adrian Roth
Principal Scientific Director Precision Safety, Pharma Development | Roche – Swiss

Michael Glaser
Safety Innovation Technology Director | GSK – USA

Ilaria Grisoni
Exec. Dir., Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals

Mariangela Amoroso
Country Medical Lead | Sanofi Italy

Lisa Stagi
Patient Safety Country Cluster Lead | Roche

Nancy Dreyer
Chief Scientific Officer retired IQVIA and Professor | Univ of North Carolina, Chapel Hill – USA

Michael Von Forstner
Head of Safety Science| Sobi

Fabio De Gregorio
Vice President, Head of Safety | Shionogi Europe – UK

Klaudija Marijanovic Barac
Sr. Director, Head of Teva Periodic reports and risk management Centre | Teva

Antonella Fretta
Senior Director | Pfizer

Valentina Strammiello
Interim Executive Director | European Patients’ Forum

Alberto Gramaccioli
Director of Quality Management and Inspection | Pfizer

Sabine Fuerst-Recktenwald
Head Clinical Development Pediatric Center of Excellence | Novartis Pharma AG

Snehal Haribhau Gaykar
Associate Director, Global Risk Management | Sandoz

Trevor Mill
Senior Vice President | SSI Strategy

Maddalena Lino
Safety Risk Lead Director | Pfizer

Paola Kruger
Expert Patient | EUPATI (European Patient’s Academy for Therapeutic Innovation)

David Chonzi
Medical Director | PV Safety Solutions

Mercedina del Papa
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance

Elena Alcaraz
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance

Sara Vodanovic
Director, Regulatory Intelligence and Analytics | PrimeVigilance

Dimitris Zampatis
Director Product Patient Safety (DPPS) | Sandoz

Catherine Tchinou
Head Medical Safety Biopharma | Sandoz

Igor Copot
Executive Director of Safety Systems | Primevigilance

Gabrièle Piaton-Breda
Research & Innovation Director | PLG
MEDIA PARTNER/COLLABORATIONS/SPONSORS 2025 IN PROGRESS
Sage
Scientific Media Partner

Sage
Scientific Media Partner
Published by SAGE, Therapeutic Advances in Drug Safety (Impact Factor: 3.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: shasha.sharief@sagepub.co.uk
Twitter: @TADrugSafety
Visit our website »
Institute of Pharmacovigilance
Collaboration

Institute of Pharmacovigilance
Collaboration
Founded in 2015, the Institute of Pharmacovigilance (IPV) is a not-for-profit, non-governmental global organization with a clear goal – to elevate the pharmacovigilance industry by competency and seniority certification.
In 2020, IPV partnered with the International Society of Pharmacovigilance (ISoP) to develop the Global Pharmacovigilance Professional Certification (GPPC), creating a globally recognized standard for PV professionals. The certification works with competency standards including knowledge, skills and attitudes suitable for every role in pharmacovigilance.
Committed to continuous innovation, IPV regularly updates its programs to reflect the latest advancements, ensuring certified professionals have practical knowledge and skills they can apply in their jobs immediately.
Visit our website »
Baupharma
Silver Sponsor

Baupharma
Silver Sponsor
Baupharma, headquartered in Prague, is a premier pharmaceutical service provider with over 25 years of industry experience. Our international team offers comprehensive services—including pharmacovigilance, regulatory affairs, medical writing, batch release and distribution, translations, and clinical research—across the EU, MENA region, CIS, Africa, USA, LATAM, and beyond. With offices in Czech Republic, Saudi Arabia, UAE and Egypt, we ensure efficient project management and collaboration, delivering tailored solutions that meet the unique needs of each market.
Visit our website »
Clinpharma
Exhibitor

Clinpharma
Exhibitor
Clinpharma was born from the desire to offer our customers, operating in the chemical-pharmaceutical sector , a complete range of consultancy services. Each project represents an opportunity for us to demonstrate a solid set of skills and make use of a vast wealth of resources. Our objective is to provide a complete consultancy service to Pharmaceutical companies relating to pharmacovigilance activities (pre and post-marketing), cosmetovigilance, phytovigilance and Supervision of Medical Devices, Regulatory Affairs, Scientific Service, Market access and preparation of the price and reimbursement dossier . The company provides its consultancy in compliance with current European and national regulations and guidelines.
Visit our website »
Insuvia
Exhibitor

Insuvia
Exhibitor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visit our website »
iVigee
Platinum Sponsor

iVigee
Platinum Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the ‘instant pharmacovigilance department’, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visit our website »
MakingLife
Media Partner

MakingLife
Media Partner
MakingLife is a publishing house and communications agency specializing in the pharmaceutical sector. It combines editorial expertise with strategic communication to provide high-value scientific content for B2B audiences. Through magazines (papaer and digital) and digital platforms, such as the MakingConnect community, MakingLife supports pharmaceutical companies and their supply chain in improving visibility and promoting innovation. Its multidisciplinary team combines scientific accuracy, creative storytelling and market knowledge to design communication tools. Furthermore, through MakingEducation, MakingLife offers its customers a training service dedicated to the pharma sector.
Visit our website »
Max Application
Exhibitor

Max Application
Exhibitor
Max Application is an IT company specialized in software solutions and focused on continuity, competence and passion in service.
Oracle partner for over 20 years, it offers cloud and on-premise solutions for sectors such as textile manufacturing, automotive and in mainly healthcare. The flagship of the latter is SafetyDrugs, the leading safety database for pharmacovigilance in Italy, accompanied by the Business Intelligence module, essential for Signal Detection.
Always committed to innovation, now part of Abacus Group, it benefits from the synergies and opportunities offered by this strategic partnership in areas such as IT infrastructure, cybersecurity, system integration and artificial intelligence.
Visit our website »
Medical Affairs Consulting
Exhibitor

Medical Affairs Consulting
Exhibitor
Our goal is to ensure excellence in Pharmacovigilance, Medical Information and promoting a culture of Change in a Kaizen perspective throughout the drug life cycle.
Since 2001, our team has provided in-depth experience in the pharmaceutical industry to support our Clients’ needs in managing:
– complex pharmacovigilance processes (QPPV, Deputy-QPPV, safety database, case-processing, aggregated reports, signal detection, literature search, Eudravigilance, Art.57, QAPV, SOPs);
– Scientific training activities for the sales force.
– Support for the preparation, in compliance with the current regulations, of advertising and scientific information materials for pharmaceutical and medical device companies.
– Management consultancy with expertise in Lean Thinking and Kaizen Culture.
Visit our website »
Nextrove
Exhibitor

Nextrove
Exhibitor
Nextrove is a global life sciences systems integrator and professional services leader, trusted by over 150 organizations worldwide — including the top 10 pharma.
We solve complex challenges and deliver end-to-end solutions: from developing and hosting technology to system migrations, upgrades, and managed services across the entire pharmacovigilance chain.
Our proprietary Progressive Suite is system-agnostic technology designed for seamless integration, augmenting organization’ existing setups, while enabling smooth workflows and operational efficiency.
Dedicated exclusively to Pharmaceutical, Biotech, and CROs, Nextrove empowers organizations to optimize operations, strengthen compliance, and deliver safer outcomes for patients — empowering pharmaceutical companies to improve patient safety.
Visit our website »
NostraPharma
Gold Sponsor

NostraPharma
Gold Sponsor
Founded in 2008, NostraPharma is a leading consultancy with ISO 9001:2015 certification, specializing in pharmacovigilance (PV), quality, and training. With over 900 years of combined expertise, we offer customized, high-quality solutions to support clients throughout the PV and quality lifecycle. Our commitment to excellence ensures personalized services, enabling businesses to confidently navigate regulatory requirements. Key services include strategic PV/Quality consultancy, AI/algorithm and GxP auditing, QPPV, PSMF, inspection support, and PV system setup and improvement. We excel in managing complex situations, providing clients with the expertise to overcome regulatory challenges effectively and efficiently.
Visit our website »
PrimeVigilance
Gold Plus Sponsor

PrimeVigilance
Gold Plus Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan. Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs. PrimeVigilance provides pharmacovigilance solutions to over 300 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases, stretching to more than 100 countries.
Visit our website »
ProductLife Group/Pharma D&S/LifeBee/Callisto Pharma Group
Exhibitor

ProductLife Group/Pharma D&S/LifeBee/Callisto Pharma Group
Exhibitor
ProductLife Group’s mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions.
Since 30 years, PLG supports clients through the entire product life cycle, combining local expertise with global reach spanning more than 150 countries. It provides consulting and outsourcing services in the areas of regulatory affairs, quality and compliance, market access, vigilances and medical information, covering both established products and innovative therapeutics & diagnostics.
With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.
Visit our website »
RxLogix
Exhibitor

RxLogix
Exhibitor
Ensuring patient safety while advancing medical and scientific research is vital to life sciences companies. RxLogix is a one-stop-shop for all pharmacovigilance needs, applying the most recent technology advances like machine learning, artificial intelligence, and best practice methodological approaches. RxLogix experienced team of business and technology innovators work with pharmacovigilance and risk management professionals to help increase the compliance, productivity, and quality for the entire drug safety value chain thus ensuring patient safety.
Visit our website to learn more or to schedule a demo.
Visit our website »
Become a sponsor
Don’t miss the chance to be a European Pharmacovigilance Congress 2025 sponsor!
Contact us to learn about our sponsorship packages, you will have the opportunity to:
• Deliver a talk in person or online
• Conduct a parallel session during the day in Milan
• Network and connect with your target customers
Conference Venue
Step 1
On November 19-20 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
COCKTAIL DINNER November 27, 2025 (NH Milano Congress Centre, in Assago, Milan)
Let’s finally meet face to face in Milan on November 28! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
PLEASE NOTE:
Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
By plane
From Malpensa Airport:
-
- take the bus to the central station, then the subway towards Assago Milanofiori Forum
- take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.
From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.
By train
From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.
By tram
From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.
Sign up for the conference
Face to Face (28/11/25) | 400€ |
Virtual (19-20/11/25) | 600€ |
Virtual + Face to Face (19-20/11/25 e 28/11/25) | 750€ |
PLEASE NOTE: Ticket options labeled ‘+ Visa’ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
* Hospitals, Universities and freelancers get a 40% discount on published prices (discounts cannot be combined).











